Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells $1,905,421.44 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 10,088 shares of the firm’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the sale, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This represents a 8.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

• On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The shares were sold at an average price of $165.49, for a total transaction of $48,654.06.

Twist Bioscience Trading Up 8.7%

TWST stock traded up $16.33 during trading on Monday, reaching $205.00. The company had a trading volume of 3,203,579 shares, compared to its average volume of 1,622,926. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $207.90. The business has a 50 day moving average of $136.40 and a 200 day moving average of $92.42. The company has a market cap of $12.86 billion, a P/E ratio of -92.34 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter last year, the company posted $0.33 EPS. The firm’s revenue was up 23.2% on a year-over-year basis. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Twist Bioscience in the 2nd quarter worth about $600,191,000. William Blair Investment Management LLC bought a new stake in shares of Twist Bioscience in the second quarter worth approximately $223,722,000. Bank of America Corp DE purchased a new position in shares of Twist Bioscience during the second quarter valued at approximately $94,922,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Twist Bioscience during the first quarter valued at approximately $22,563,000. Finally, BNP Paribas Financial Markets lifted its position in Twist Bioscience by 242.2% during the fourth quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company’s stock valued at $13,183,000 after purchasing an additional 294,144 shares during the period.

Key Headlines Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company’s expansion narrative and helping support bullish sentiment. Twist Bioscience stock reports 23 percent revenue growth
• Positive Sentiment: Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. Leerink raises target for Twist Bioscience stock
• Positive Sentiment: The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. Twist Bioscience reaches new 52-week high
• Neutral Sentiment: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO’s sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. Twist Bioscience insider transaction filing
• Negative Sentiment: Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink’s revised target, increasing the potential for volatility or profit-taking.

Analyst Ratings Changes

TWST has been the topic of a number of recent research reports. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price on the stock. in a research report on Monday, July 6th. Barclays boosted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $115.27.

About Twist Bioscience

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.